The use of recently approved antiepileptic drugs: use with caution, use in refractory patients or use as first-line indications?

References

• Abimbola S, Martiniuk AL, Hackett ML, Anderson CS. The influence of design and definition on the proportion of general epilepsy cohorts with remission and intractability. Neuroepidemiology36, 204–212 (2011).
   PubMed Web of Science ®Google Scholar
• Rodin EA. The Prognosis of Patients with Epilepsy. Charles C. Thomas Springfield, IL, USA (1968).
   Google Scholar
• Sillanpää M, Schmidt D. Early seizure frequency and aetiology predict long-term medical outcome in childhood-onset epilepsy. Brain132, 989–998 (2009).
   PubMed Web of Science ®Google Scholar
• Geerts A, Arts WF, Stroink H et al. Course and outcome of childhood epilepsy: a 15-year follow-up of the Dutch study of epilepsy in childhood. Epilepsia51, 1189–1197 (2011).
   Google Scholar
• Berg AT, Shinnar S, Levy SR et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia42, 1553–1562 (2001).
   PubMed Web of Science ®Google Scholar
• MacDonald BK, Johnson AL, Goodridge DM, Cockerell OC, Sander JW, Shorvon SD. Factors predicting prognosis of epilepsy after presentation with seizures. Ann. Neurol.48, 833–841 (2000).
   PubMed Web of Science ®Google Scholar
• Collaborative Group for the Study of Epilepsy. Prognosis of epilepsy in newly referred patients: a multicenter prospective study of the effects of monotherapy on the long-term course of epilepsy. Epilepsia33, 45–51 (1992).
   PubMed Web of Science ®Google Scholar
• Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia20, 729–737 (1979).
   PubMed Web of Science ®Google Scholar
• Camfield PR, Camfield CS, Gordon K, Dooley JM. If a first antiepileptic drug fails to control a child’s epilepsy, what are the chances of success with the next drug? J. Pediatr.131, 821–824 (1997).
   PubMed Web of Science ®Google Scholar
• Dlugos DJ, Sammel MD, Strom BL, Farrar JT. Response to first drug trial predicts outcome in childhood temporal lobe epilepsy. Neurology57, 2259–2264 (2001).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med.342, 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Choi H, Heiman GA, Munger Clary H, Etienne M, Resor SR, Hauser WA. Seizure remission in adults with long-standing intractable epilepsy: an extended follow-up. Epilepsy Res.93, 115–119 (2011).
   PubMed Web of Science ®Google Scholar
• Del Felice A, Beghi E, Boero G et al. Early versus late remission in a cohort of patients with newly diagnosed epilepsy. Epilepsia51, 37–42 (2010).
   PubMedGoogle Scholar
• Sillanp ää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain129, 617–624 (2006).
   PubMedGoogle Scholar
• Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol.62, 382–389 (2007).
   PubMed Web of Science ®Google Scholar
• Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann. Neurol.62, 375–381 (2007).
   PubMed Web of Science ®Google Scholar
• Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909–1958. Epilepsia50(Suppl. 3), 69–92 (2009).
   PubMedGoogle Scholar
• Shorvon SD. Drug treatment of epilepsy in the century of the ILAE: the second 50 years, 1959–2009. Epilepsia50(Suppl. 3), 93–130 (2009).
   PubMed Web of Science ®Google Scholar
• Arroyo S. Rufinamide. Neurotherapeutics4, 155–162 (2007).
   PubMed Web of Science ®Google Scholar
• Perucca E. An introduction to antiepileptic drugs. Epilepsia46(Suppl. 4), 31–37 (2005).
   PubMed Web of Science ®Google Scholar
• Rogawski MA, Loscher W. The neurobiology of antiepileptic drugs. Nat. Rev. Neurosci.5, 553–564 (2004).
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs25, 89–107 (2011).
   PubMed Web of Science ®Google Scholar
• Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev. Neurother.10, 119–140 (2010).
   PubMed Web of Science ®Google Scholar
• Schmitz B, Montouris G, Schauble B, Caleo S. Assessing the unmet treatment need in partial-onset epilepsy: looking beyond seizure control. Epilepsia51, 2231–2240 (2010).
   PubMed Web of Science ®Google Scholar
• Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin. Pharmacokinet.45, 351–363 (2006).
   PubMed Web of Science ®Google Scholar
• Beghi E, Atzeni L, Garattini L Economic analysis of newer antiepileptic drugs. CNS Drugs22, 861–875 (2008).
   PubMed Web of Science ®Google Scholar
• Costa J, Fareleira F, Ascencao R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia52, 1280–1291 (2011).
   PubMed Web of Science ®Google Scholar
• Lozsadi D, Hemming K, Marson AG. Pregabalin add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev.1, CD005612 (2008).
   Google Scholar
• Hemming K, Maguire MJ, Hutton JL, Marson AG. Vigabatrin for refractory partial epilepsy (review). Cochrane Database Syst. Rev.3, CD007302 (2008).
   Google Scholar
• Jette N, Hemming K, Hutton JL, Marson AG. Topiramate add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev.2, CD001417 (2008).
   Google Scholar
• Chadwick DW, Marson AG. Zonisamide add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev.2, CD001416 (2005).
   Google Scholar
• Pereira J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev.3, CD001908 (2002).
   Google Scholar
• Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant localization-related (partial) epilepsy (review). Cochrane Database Syst. Rev.1, CD001901 (2001).
   PubMedGoogle Scholar
• Ramaratnam S, Marson AG, Baker GA. Lamotrigine add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev.3, CD001909 (2001).
   Google Scholar
• Castillo SM, Schmidt DB, White S, Shukralla A. Oxcarbazepine add-on for drug-resistant partial epilepsy (review). Cochrane Database Syst. Rev.3, CD002028 (2000).
   Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet369(9566), 1000–1015 (2007).
   PubMed Web of Science ®Google Scholar
• Gamble CL, Williamson PR, Marson AG. Lamotrigine versus carbamazepine monotherapy for epilepsy (review). Cochrane Database Syst. Rev.1, CD001031 (2006).
   Google Scholar
• Saetre E, Perucca E, Isojärvi J, Gjerstad L; LAM 40089 Study Group. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia48, 1292–1302 (2007).
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet369(9566), 1016–1026 (2007).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ, Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology68, 402–408 (2007).
   PubMed Web of Science ®Google Scholar
• Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S; EPMN 105 Study Group. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol. Scand.107, 165–175 (2003).
   PubMed Web of Science ®Google Scholar
• Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet354, 13–19 (1999).
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia47, 1094–1120 (2006).
   PubMed Web of Science ®Google Scholar
• French JA, Kanner AM, Bautista J et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology62, 1261–1273 (2004).
   PubMed Web of Science ®Google Scholar
• Pellock JM, Hrachovy R, Shinnar S et al. Infantile spasms: a US. consensus report. Epilepsia51, 2175–2189 (2010).
   PubMed Web of Science ®Google Scholar
• Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database Syst. Rev.4, CD001770 (2008).
   Google Scholar
• Dravet C. Dravet syndrome history. Dev. Med. Child Neurol.53(Suppl. 2), 1–6 (2011).
   PubMedGoogle Scholar
• Kassaï B, Chiron C, Augier S et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia49, 343–348 (2008).
   PubMed Web of Science ®Google Scholar
• Arzimanoglou A, French J, Blume WT et al. Lennox–Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol.8, 82–93 (2009).
   PubMed Web of Science ®Google Scholar
• Hancock EC, Cross HH. Treatment of Lennox–Gastaut syndrome. Cochrane Database Syst. Rev.3, CD003277 (2009).
   Google Scholar
• Verrotti A, Loiacono G, Ballone E, Mattei PA, Chiarelli F, Curatolo P. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr. Neurol.44, 347–349 (2011).
   PubMedGoogle Scholar
• Prunetti P, Perucca E. New and forthcoming anti-epileptic drugs. Curr. Opin. Neurol.24, 159–164 (2011).
   PubMed Web of Science ®Google Scholar
• Depositario-Cabacar DF, Zelleke TG. Treatment of epilepsy in children with developmental disabilities. Dev. Disabil. Res. Rev.16, 239–247 (2010).
   PubMedGoogle Scholar
• Beavis J, Kerr M, Marson AG. Pharmacological interventions for epilepsy in people with intellectual disabilities (review). Cochrane Database Syst. Rev.3, CD005399 (2007).
   Google Scholar
• Kaufman DW, Kelly JP, Anderson T, Harmon DC, Shapiro S. Evaluation of case reports of aplastic anemia among patients treated with felbamate. Epilepsia38, 1265–1269 (1997).
   PubMed Web of Science ®Google Scholar
• Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens–Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology64, 1134–1138 (2005).
   PubMed Web of Science ®Google Scholar
• Willmore LJ, Abelson MB, Ben-Menachem E, Pellock JM, Shields WD. Vigabatrin: 2008 update. Epilepsia50, 163–173 (2009).
   PubMed Web of Science ®Google Scholar
• Tomson T, Battino D, Bonizzoni E et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol.10, 609–617 (2011).
   PubMed Web of Science ®Google Scholar
• Molgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA305, 1996–2002 (2011).
   PubMed Web of Science ®Google Scholar
• Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord.6, 57–75 (2004).
   PubMed Web of Science ®Google Scholar
• Amann B, Born C, Crespo JM, Pomarol-Clotet E, McKenna P. Lamotrigine: when and where does it act in affective disorders? A systematic review. J. Psychopharmacol. doi:10.1177/0269881110376695 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Zaccara G, Messori A, Cincotta M, Burchini G. Comparison of the efficacy and tolerability of new antiepileptic drugs; what can we learn from long-term studies? Acta Neurol. Scand.114, 157–168 (2006).
   PubMed Web of Science ®Google Scholar
• Weijenberg A. Offringa M, Brouwer OF, Callenbach PM. RCTs with new antiepileptic drugs in children: a systematic review of monotherapy studies and their methodology. Epilepsy Res.91, 1–19 (2010).
   PubMedGoogle Scholar
• Dogan EA, Usta BE, Bilgen R, Senol Y, Aktekin B. Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behav.13, 156–161 (2008).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Chadwick DW, Anhut H et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia43, 993–1000 (2002).
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia42, 1255–1260 (2001).
   PubMed Web of Science ®Google Scholar
• Begley CE, Annegers JF, Lairson DR, Reynolds TF, Hauser WA. Cost of epilepsy in the United States: a model based on incidence and prognosis. Epilepsia35, 1230–1243 (1994).
   PubMed Web of Science ®Google Scholar
• Glauser TA, Cnaan A, Shinnar S et al. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N. Engl. J. Med.362, 790–799 (2010).
   PubMed Web of Science ®Google Scholar
• Loscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia52, 657–678 (2011).
   PubMed Web of Science ®Google Scholar
• Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov.9, 68–82 (2010).
   PubMed Web of Science ®Google Scholar